Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Nora Liebers, Peter-Martin Bruch, Agnes Gambietz, Holly Giles, BA, Junyan Lu, PhD, Mareike Knoll, Carolin Kolb, Peter Dreger, Carsten Mueller-Tidow, MD, Wolfgang Huber, PhD, Axel Benner, Thorsten Zenz, MD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 376.

https://doi.org/10.1182/blood-2019-125324

Published: 2019

Journal Articles

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Jun Zhu, MD, Ee-Min Yeoh, BSc, Yoshinobu Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 5290.

https://doi.org/10.1182/blood-2019-124080

Published: 2019

Journal Articles

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Zachary D. Epstein-Peterson, MD, Paola Ghione, MD, Alison J. Moskowitz, MD, Parastoo B. Dahi, MD, Ahmet Dogan, MD PhD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, Miguel-Angel Perales, MD, Doris M Ponce, MD, David J. Straus, MD, Andrew D. Zelenetz, MD PhD, Craig S. Sauter, MD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2850.

https://doi.org/10.1182/blood-2019-125376

Published: 2019

Journal Articles

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Helen Ma, MD, Enrica Marchi, MD, PhD, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 3486.

https://doi.org/10.1182/blood-2019-123587

Published: 2019

Journal Articles

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark

Justin Taylor, Michael Haddadin, Vivek A. Upadhyay, Erwin Grussie, Neha Mehta-Shah, Andrew M. Brunner, Abner Louissaint, Jr, Scott B. Lovitch, Ahmet Dogan, Amir T. Fathi, Richard M. Stone, Martin S. Tallman, Raajit K. Rampal, Donna S. Neuberg, Kristen E. Stevenson, Steven M. Horwitz, Andrew A. Lane

Blood (2019) 134 (8): 678–687.

https://doi.org/10.1182/blood.2019001144

Published: 2019

Includes: Supplemental data

Journal Articles

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

Kana Oiwa, MD, Naoko Hosono, MD, Rie Nishi, PhD, Takanori Ueda, MD PhD, Luigi Scott, PhD, Owen A. O'Connor, MD, PhD, Takahiro Yamauchi, MD PhD

Blood (2018) 132 (Supplement 1): 3961.

https://doi.org/10.1182/blood-2018-99-110147

Published: 2018

Journal Articles

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Robert Stuver, MD, Niloufer Khan, MD, Marc Schwartz, Mark Acosta, Massimo Federico, MD, Christian Gisselbrecht, Frederick Lansigan, MD, Lauren C. Pinter-Brown, MD, Barbara Pro, MD, Andrei R. Shustov, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Salvia Jain, MD

Blood (2018) 132 (Supplement 1): 2926.

https://doi.org/10.1182/blood-2018-99-112869

Published: 2018

Journal Articles

Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) — Results from a Prospective Multicenter Phase 2 Clinical Trial

Andrei R Shustov, MD, Michi M Shinohara, MD, Shaker R. Dakhil, MD, Gajanan Bhat, Jasmine M. Zain, MD

Blood (2018) 132 (Supplement 1): 2910.

https://doi.org/10.1182/blood-2018-99-119684

Published: 2018

Journal Articles

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Jennifer E. Amengual, Renee Lichtenstein, Jennifer Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine Atkins, Aishling Rada, Hye A. Kim, Codruta Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, Mark A. Francescone, Lawrence Schwartz, Serge Cremers, Owen A. O’Connor

Blood (2018) 131 (4): 397–407.

https://doi.org/10.1182/blood-2017-09-806737

Published: 2018

Includes: Supplemental data

Journal Articles

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Andrei Shustov, MD, Patrick B Johnston, MD PhD, Stefan Klaus Barta, MDMRCP,MS, Gajanan Bhat, Guru Reddy, Yasuhiro Oki, MD

Blood (2017) 130 (Supplement 1): 818.

https://doi.org/10.1182/blood.V130.Suppl_1.818.818

Published: 2017

Journal Articles

Peripheral T-cell lymphoma, not otherwise specified

Alessandro Broccoli, Pier Luigi Zinzani

Blood (2017) 129 (9): 1103–1112.

https://doi.org/10.1182/blood-2016-08-692566

Published: 2017

Journal Articles

Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate

Owen A. O'Connor, MD PhD, Enrica Marchi, MD PhD, Weining Volinn, PhD, Won Seog Kim, MD PhD

Blood (2016) 128 (22): 4149.

https://doi.org/10.1182/blood.V128.22.4149.4149

Published: 2016

Journal Articles

Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study

Frederick Lansigan, MD, Steven M Horwitz, MD, Lauren C Pinter-Brown, MD, Kenneth R Carson, MD, Andrei R Shustov, MD, Steven T. Rosen, MD, Barbara Pro, MD, Eric D. Hsi, MD, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A Bellm, MIM, Mark Acosta, PharmD, Francine M. Foss, MD

Blood (2016) 128 (22): 4150.

https://doi.org/10.1182/blood.V128.22.4150.4150

Published: 2016

Journal Articles

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

Janie Y Zhang, MD, Robert Briski, BS, Sumana Devata, MD, Mark S Kaminski, MD, Tycel Phillips, MD, Tera Mayer, NP, Nathanael G Bailey, MD, Ryan A Wilcox, MD PhD

Blood (2016) 128 (22): 4152.

https://doi.org/10.1182/blood.V128.22.4152.4152

Published: 2016

Journal Articles

Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Yoshinobu Maeda, MD PhD, Kensei Tobinai, MD, PhD, Hirokazu Nagai, MD PhD, Takahiko Nakane, MD, PhD, Tatsu Shimoyama, MD, Tomonori Nakazato, Rika Sakai, Takayuki Ishikawa, MD, PhD, Koji Izutsu, MD PhD, Ryuzo Ueda, MD PhD

Blood (2016) 128 (22): 4157.

https://doi.org/10.1182/blood.V128.22.4157.4157

Published: 2016

Journal Articles

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

Matko Kalac, MD PhD, Cristine Candland, RN, Lisa Wallace, RN, Elizabeth Gentner, RN, Shreya Shah, Jennifer E Amengual, MD, Changchun Deng, MD PhD, Suzanne Lentzsch, MD PhD, Owen A. O'Connor, MD PhD, Markus Y Mapara, MD PhD

Blood (2016) 128 (22): 5834.

https://doi.org/10.1182/blood.V128.22.5834.5834

Published: 2016

Journal Articles

CHOP in Combination with Pralatrexate, a Novel Folate Analogue Metabolic Inhibitor in Patients with Previously Untreated Peripheral T-Cell Lymphoma (PTCL): Interim Results of the Phase 1 Trial

Andrei R. Shustov, MD, Yasuhiro Oki, MD, Stefan Klaus Barta, MD MRCP, MS, Patrick B. Johnston, MD PhD, Pankaj Sharma, Tao Song, Sanjay Mourya

Blood (2016) 128 (22): 5355.

https://doi.org/10.1182/blood.V128.22.5355.5355

Published: 2016

Journal Articles

Clinical Research and Genomic Analysis on Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma with Chidamide Monotherapy

Yu Wu, MD & PhD, Juan Xu, MD, Yuan Tang, MD, Yongqian Jia, MD

Blood (2016) 128 (22): 5287.

https://doi.org/10.1182/blood.V128.22.5287.5287

Published: 2016

Journal Articles

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Jennifer E Amengual, MD, Renee Lichtenstein, Celeste Rojas, Ahmed Sawas, MD, Changchun Deng, MD PhD, Emily Lichtenstien, Karen Kahn, Jennifer Kimberly Lue, MD, Yuxuan Liu, PhD, Changhong Qiao, Renu Nandakumar, PhD, Serge Cremers, PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 1824.

https://doi.org/10.1182/blood.V128.22.1824.1824

Published: 2016

NARROW

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) — Results from a Prospective Multicenter Phase 2 Clinical Trial

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Peripheral T-cell lymphoma, not otherwise specified

Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate

Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

CHOP in Combination with Pralatrexate, a Novel Folate Analogue Metabolic Inhibitor in Patients with Previously Untreated Peripheral T-Cell Lymphoma (PTCL): Interim Results of the Phase 1 Trial

Clinical Research and Genomic Analysis on Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma with Chidamide Monotherapy

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only